These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 18059033)

  • 1. Dickkopf-3 expression is a marker for neuroblastic tumor maturation and is down-regulated by MYCN.
    Koppen A; Ait-Aissa R; Koster J; Øra I; Bras J; van Sluis PG; Caron H; Versteeg R; Valentijn LJ
    Int J Cancer; 2008 Apr; 122(7):1455-64. PubMed ID: 18059033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dickkopf-1 is down-regulated by MYCN and inhibits neuroblastoma cell proliferation.
    Koppen A; Ait-Aissa R; Hopman S; Koster J; Haneveld F; Versteeg R; Valentijn LJ
    Cancer Lett; 2007 Oct; 256(2):218-28. PubMed ID: 17643814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MYCN-regulated miRNA-92 inhibits secretion of the tumor suppressor DICKKOPF-3 (DKK3) in neuroblastoma.
    Haug BH; Henriksen JR; Buechner J; Geerts D; Tømte E; Kogner P; Martinsson T; Flægstad T; Sveinbjørnsson B; Einvik C
    Carcinogenesis; 2011 Jul; 32(7):1005-12. PubMed ID: 21572098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MSX1 induces the Wnt pathway antagonist genes DKK1, DKK2, DKK3, and SFRP1 in neuroblastoma cells, but does not block Wnt3 and Wnt5A signalling to DVL3.
    Revet I; Huizenga G; Koster J; Volckmann R; van Sluis P; Versteeg R; Geerts D
    Cancer Lett; 2010 Mar; 289(2):195-207. PubMed ID: 19815336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dickkopf-3 is regulated by the MYCN-induced miR-17-92 cluster in neuroblastoma.
    De Brouwer S; Mestdagh P; Lambertz I; Pattyn F; De Paepe A; Westermann F; Schroeder C; Schulte JH; Schramm A; De Preter K; Vandesompele J; Speleman F
    Int J Cancer; 2012 Jun; 130(11):2591-8. PubMed ID: 21796614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deregulated Wnt/beta-catenin program in high-risk neuroblastomas without MYCN amplification.
    Liu X; Mazanek P; Dam V; Wang Q; Zhao H; Guo R; Jagannathan J; Cnaan A; Maris JM; Hogarty MD
    Oncogene; 2008 Feb; 27(10):1478-88. PubMed ID: 17724465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vasoactive intestinal peptide decreases MYCN expression and synergizes with retinoic acid in a human MYCN-amplified neuroblastoma cell line.
    Chevrier L; Meunier AC; Cochaud S; Muller JM; Chadéneau C
    Int J Oncol; 2008 Nov; 33(5):1081-9. PubMed ID: 18949372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study on the role of MYCN in retinoblastoma by inhibiting p53 and activating wnt/βcatenin/Fra-1 signaling pathway by reducing DKK3.
    Chen X; Ouyang L; Ke N; Pi L; Zhou X
    Drug Dev Res; 2024 Aug; 85(5):e22222. PubMed ID: 39003564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of cyclin-dependent kinase 1-induced cell death in neuroblastoma cells through the microRNA-34a-MYCN-survivin pathway.
    Chen Y; Tsai YH; Tseng SH
    Surgery; 2013 Jan; 153(1):4-16. PubMed ID: 22703967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell cycle regulation targets of MYCN identified by gene expression microarrays.
    Bell E; Lunec J; Tweddle DA
    Cell Cycle; 2007 May; 6(10):1249-56. PubMed ID: 17495526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Next-generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN-amplified neuroblastoma.
    Schramm A; Köster J; Marschall T; Martin M; Schwermer M; Fielitz K; Büchel G; Barann M; Esser D; Rosenstiel P; Rahmann S; Eggert A; Schulte JH
    Int J Cancer; 2013 Feb; 132(3):E106-15. PubMed ID: 22907398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MYCN is a novel oncogenic target in adult B-ALL that activates the Wnt/β-catenin pathway by suppressing DKK3.
    Kong D; Zhao L; Sun L; Fan S; Li H; Zhao Y; Guo Z; Lin L; Cui L; Wang K; Chen W; Zhang Y; Zhou J; Li Y
    J Cell Mol Med; 2018 Jul; 22(7):3627-3637. PubMed ID: 29673070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of a MYCN-interacting isoform of the tumor suppressor BIN1 is reduced in neuroblastomas with unfavorable biological features.
    Tajiri T; Liu X; Thompson PM; Tanaka S; Suita S; Zhao H; Maris JM; Prendergast GC; Hogarty MD
    Clin Cancer Res; 2003 Aug; 9(9):3345-55. PubMed ID: 12960121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ID2 expression in neuroblastoma does not correlate to MYCN levels and lacks prognostic value.
    Vandesompele J; Edsjö A; De Preter K; Axelson H; Speleman F; Påhlman S
    Oncogene; 2003 Jan; 22(3):456-60. PubMed ID: 12545167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GRHL1 acts as tumor suppressor in neuroblastoma and is negatively regulated by MYCN and HDAC3.
    Fabian J; Lodrini M; Oehme I; Schier MC; Thole TM; Hielscher T; Kopp-Schneider A; Opitz L; Capper D; von Deimling A; Wiegand I; Milde T; Mahlknecht U; Westermann F; Popanda O; Roels F; Hero B; Berthold F; Fischer M; Kulozik AE; Witt O; Deubzer HE
    Cancer Res; 2014 May; 74(9):2604-16. PubMed ID: 24419085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of MYCN and ID2 overexpression in neuroblastoma.
    Alaminos M; Gerald WL; Cheung NK
    Pediatr Blood Cancer; 2005 Dec; 45(7):909-15. PubMed ID: 16047351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dissection of the oncogenic MYCN transcriptional network reveals a large set of clinically relevant cell cycle genes as drivers of neuroblastoma tumorigenesis.
    Murphy DM; Buckley PG; Bryan K; Watters KM; Koster J; van Sluis P; Molenaar J; Versteeg R; Stallings RL
    Mol Carcinog; 2011 Jun; 50(6):403-11. PubMed ID: 21557326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional interplay between MYCN, NCYM, and OCT4 promotes aggressiveness of human neuroblastomas.
    Kaneko Y; Suenaga Y; Islam SM; Matsumoto D; Nakamura Y; Ohira M; Yokoi S; Nakagawara A
    Cancer Sci; 2015 Jul; 106(7):840-7. PubMed ID: 25880909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression and DNA-binding activity of MYCN/Max and Mnt/Max during induced differentiation of human neuroblastoma cells.
    Smith AG; Popov N; Imreh M; Axelson H; Henriksson M
    J Cell Biochem; 2004 Aug; 92(6):1282-95. PubMed ID: 15258910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclin D1 in pediatric neuroblastic tumors: A microarray analysis.
    Fagone P; Nicoletti F; Vecchio GM; Parenti R; Magro G
    Acta Histochem; 2015 Oct; 117(8):820-3. PubMed ID: 26510683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.